Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valeric Acid SCHEMBL28242517 | 0.78 | LMNA (0.39) | LMNAMEN1KMT2ATDP1 | |
| SCHEMBL16167221 | 0.71 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL9542690 | 0.69 | CREBBP (0.47) | MAPTMEN1KMT2A | |
| SCHEMBL11702833 | 0.69 | — | — | |
| SCHEMBL11702847 | 0.69 | — | — | |
| SCHEMBL23754724 | 0.67 | MAP3K14 (0.36) | MAP3K14CRBNCYP19A1LMNAMAPT | |
| SCHEMBL2039535 | 0.64 | — | — | |
| SCHEMBL6897659 | 0.64 | — | — | |
| SCHEMBL28727342 | 0.62 | — | — | |
| SCHEMBL1024468 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379501-B1 | METHOD FOR PREPARING ACTIVATED ESTERS | SANOFI SA (FR) | 2014-01-22 | — | — | EP | disclosed |
| CN-102292318-B | Method for preparing activated esters | SANOFI SA | 2014-01-01 | — | — | CN | disclosed |
| US-8314244-B2 | Method for preparing activated esters | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-20110313168-A1 | METHOD FOR PREPARING ACTIVATED ESTERS | SANOFI (FR) | 2011-12-22 | — | — | US | disclosed |
| EP-2379501-A1 | METHOD FOR PREPARING ACTIVATED ESTERS | SANOFI (FR) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010076474-A1 | METHOD FOR PREPARING ACTIVATED ESTERS | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | disclosed |
| US-5552541-A | Haptenic probes for detecting capture polynucleotides | BECKMAN INSTRUMENTS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0487718-A1 | NUCLEIC ACID PROBES with negatively charged haptens which are attached to the probe via a hydrazine binding moiety | BECKMAN INSTRUMENTS, INC. (US) | 1992-06-03 | — | — | EP | disclosed |
| WO-1991019729-A1 | NUCLEIC ACID PROBES AND PROTEIN PROBES | BECKMAN INSTRUMENTS, INC. (US) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313168-A1 | METHOD FOR PREPARING ACTIVATED ESTERS | C9, C1S, ALK | MAP3K14 1772/4885CRBN 2950/4885CYP19A1 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.